COMPANY PROFILE

Gala Biotech

Gala Biotech is Greek for milk, and the company's original mission is to produce pharmaceutical proteins in the milk of transgenic cows

Middleton, United StatesFounded 1996Biotech & Life Sciences

Valuation $50–100M Last recorded · 2000

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Gala Biotech

Gala.com operates a blockchain platform that facilitates fractional investment in domain names and provides proof of asset ownership. The company serves investors looking to diversify their portfolios with digital assets and domain name enthusiasts seeking partial ownership. Operating in the digital asset market, Gala.com leverages blockchain technology to ensure transparency and security in transactions. The business model revolves around transaction fees and service charges for managing and verifying asset ownership. By offering a secure and efficient way to invest in domain names, Gala.com aims to attract a broad range of clients from individual investors to institutional players.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 1996
Headquarters: Middleton, United States
Employees: 10
Open positions: None listed
Dealroom signal: 71.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Oct 2003	$0	—	Cardinal Health	—
EARLY VCEquity / VC	Jul 2000	$10M	$40M	Venture Investors Health Fund · Advantage Capital · Mason Wells	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Gala Biotech website traffic

Latest recorded traffic for Gala Biotech is 99K monthly website visits, down 23.8% over the last three months. Gala Biotech's team grew 0% over the past year.

Latest monthly visits99K 3-month web change-23.8% 1-year team growth0%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational	53	$47M	$160M
DPDalCor PharmaceuticalsPrecision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits	Montreal, Canada	Operational
PDPathogen DXDevelops a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets	Scottsdale, United States	Operational
RNRoche NimbleGenProducts and services to the life science research market	Madison, United States	Acquired
CDCancerGuide DiagnosticsMolecular diagnostics company developing genomic-based clinical and pharmaceutical cancer tests and services	Durham, United States	Closed
SPSomanta PharmaceuticalsDevelopment-stage biopharmaceutical company manufacturing therapeutic drugs for the treatment of cancer	Irvine, United States	Operational
CTCybrexa TherapeuticsA New Haven, CT-based cancer therapeutics company	New Haven, United States	Operational
APAtrin PharmaceuticalsDynamic biopharmaceutical firm focused on the discovery and development of proprietary medications	Ambler, United States	Acquired